Pulmonary arterial hypertension
Conditions
Brief summary
Change in power per beat after 24 weeks of sotatercept, Change in right ventricular pulmonary artery coupling index (Ees/Ea) after 24 weeks of sotatercept
Detailed description
∆ Right Ventricular End Diastolic Volume (RVEDV), ∆ Right Ventricular End Systolic Volume (RVESV), ∆ Right Ventricular Ejection Fraction (RVEF), ∆ Right Ventricular mass, ∆ Stroke Volume determined from aortic flow, ∆ Left Ventricular End Diastolic Volume (LVEDV), ∆ Left Ventricular End Systolic Volume (LVESV), ∆ Left Ventricular Ejection Fraction (LVEF), ∆ Left ventricular mass, ∆ End-systolic elastance (Ees), ∆ Arterial elastance (Ea), ∆ End diastolic elastance (Eed), ∆ Extracellular volume as measured by cardiac magnetic resonance imaging
Interventions
DRUGWinrevair 60 mg powder for solution for injection
Sponsors
Amsterdam UMC Stichting
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in power per beat after 24 weeks of sotatercept, Change in right ventricular pulmonary artery coupling index (Ees/Ea) after 24 weeks of sotatercept | — |
Secondary
| Measure | Time frame |
|---|---|
| ∆ Right Ventricular End Diastolic Volume (RVEDV), ∆ Right Ventricular End Systolic Volume (RVESV), ∆ Right Ventricular Ejection Fraction (RVEF), ∆ Right Ventricular mass, ∆ Stroke Volume determined from aortic flow, ∆ Left Ventricular End Diastolic Volume (LVEDV), ∆ Left Ventricular End Systolic Volume (LVESV), ∆ Left Ventricular Ejection Fraction (LVEF), ∆ Left ventricular mass, ∆ End-systolic elastance (Ees), ∆ Arterial elastance (Ea), ∆ End diastolic elastance (Eed), ∆ Extracellular volume as measured by cardiac magnetic resonance imaging | — |
Countries
Netherlands
Outcome results
None listed